Intranasal Delivery of Nano Neurotherapeutics: A Meta Opinion

The most stringer barrier for the delivery of neurotherapeutics in-vivo is presented by the blood-brain barrier which limits the access of neurotherapeutics to the CNS effectively. Intranasal delivery of neurotherapeutics is one of the promising endeavors to surmount the blood-brain barrier, designated as direct nose to brain transport, by the passage of neurotherapeutics along the olfactory and trigeminal nerve pathways. The outstanding findings obtained from the nanomedicines in the preclinical studies for the treatment of CNS disorders via intranasal administration have harnessed the scientists from various research groups to walk around the nano neurotherapeutics for the effective management of CNS disorders. Currently, 33 nanotherapeutics and 67 commercialized nanodevices are on the market but none of them is a nano neurotherapeutic. This could be attributed to the fact that though the researchers have obtained outstanding preclinical findings but these were followed by the disappointing clinical results. To conclude in summary, the authors want to mention here that the development of targets-specific nano pharmaceuticals delivered via non-invasive intranasal route of administration might present some hope to the development of novel neurotherapeutics for major CNS disorders. According to our assessment, in order to come out with a newly designed neurotherapeutic with optimized physicochemical, pharmacological, and pharmacokinetic properties, it requires several parameters to be studied in silico, in-vitro, and in-vivo, keeping in mind the complex nature of the brain.